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Tumors like glioblastoma are inaccessible due to blood brain barrier. The perme-
ability of radioisotopes can be improved by conjugating them with nanoparticles. 
The most common malignant adult brain tumor is glioblastoma, which has very 
poor patient prognosis. The mean survival for highly proliferative glioblastoma is 
only 10–14 months despite an aggressive radiotherapy and chemotherapy follow-
ing debulking surgery. β− particle emitters like 131I, 90Y, 186/188Re, and 177Lu have 
been coupled with nanoparticles and used for treatment of glioblastoma. These 
radiopharmaceutical compounds have resulted in a stabilization and improvement 
of the neurological status with minimal side effects. Similarly, α particle emit-
ters like 213Bi, 211At, and 225Ac are an innovative and interesting alternative. Alpha 
particles deliver a high proportion of their energy inside the targeted cells within a 
few micrometers from the emission point versus several millimeters for β− particles. 
Thus, α particles are highly efficient in killing tumor cells with minimal irradia-
tion of healthy tissues and permits targeting of isolated tumor cells. This has been 
confirmed by subsequent clinical trials which showed better therapeutic efficacy 
and minimal side effects, thus opening a new and promising era for glioblastoma 
medical care using α therapy.
Keywords: radioisotopes, nanoparticles, brain targeting, glioblastoma, blood brain 
barrier, theranostics
1. Introduction
Nuclear medicine involves use of radioactive atoms for diagnosis and/or therapy. 
For therapeutic purposes, to obtain specific irradiation of tumor cells, radioactivity 
is attached to a pharmaceutical molecule that binds to specific molecules expressed 
on the target tumor cells. This specific radioactive molecule is known as radio-
pharmaceutical. The pharmacological specific component of a therapeutic radio-
pharmaceutical can be based on the target protein structure which may include 
peptides or monoclonal antibodies, or molecular structures like nanoparticles [1]. 
The radioactive part may consist of massive particle emitters capable of delivering 
ionizing energy locally as Auger electrons, or β− or α particles. Auger electrons are 
low-energy electrons that emit localized irradiation, few nanometers around the 
emission point with high biological effects. Beta-negative particles have a compara-
tively low linear energy transfer (LET) and emit their energy over a few millimeters 
in comparison to alpha particles. The choice of the radionuclide is based upon the 
size of the tumor. For example, yttrium-90 emits a long-range beta emission and 
could be useful for proliferating tumors of large size, while lutetium-177 having a 
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short range emission could be used for treatment retreating tumors of small size. 
Alpha particles deliver a high fraction of their energy inside the targeted cells, lead-
ing to highly efficient killing. This makes them suitable for targeting cells of isolated 
tumor and minimal residual disease [2, 3].
Radioimmunotherapy, radiopeptide therapy and radionanoparticles are three 
important strategies of nuclear medicine for glioblastoma therapy. The four main 
prerequisites for successful radionuclide therapy for glioblastoma are selection of 
an appropriate target (integrin, tenascin, cadherin, EGFR, chemokine receptors or 
neurokinin receptors), physicochemical properties of the radionuclide, physico-
chemical properties of the targeting vector and its size [5]. For therapeutic purposes, 
nuclear medicine practitioners typically use β− particle emitters like 131I, 90Y, 186/188Re, 
and 177Lu. These radioisotopes have been coupled with nanoparticles, monoclonal 
antibodies, or peptides for treatment of glioblastoma. These radiopharmaceuticals 
have resulted in maintenance and/or improvement of the neurological status with 
only short-term side effects. The evidence for glioblastoma targeted radiotherapy has 
not only proven for β− particle emitters but also for α particle emitters. 213Bi, 211At, 
and 225Ac are some of the particle emitters which are recently attracting the interest 
of the scientific community. They are capable of delivering high amount of their 
energy within few micrometers close to their emission point in comparison to some 
few millimeters for β− particles. The α particles have been found highly efficient in 
killing tumor cells with minimal irradiation of healthy tissues and permits targeting 
of isolated tumor cells [1, 4].
2. Understanding WHO Classification of CNS tumors
Gliomas are the most frequent, very diverse group of intrinsic tumors of the 
central nervous system and are conventionally classified in harmony to their 
microscopic alikeness with recognized cells of origin according to glial precursor 
cell families. Major groups consist of diffuse gliomas, categorized by widespread 
growth into the adjoining CNS parenchyma, and more confined “nondiffuse” 
gliomas, with pilocytic astrocytoma and ependymomas [6]. The fourth edition of 
the WHO Classification of CNS tumors published in 2016 has essentially changed 
the classification of diffuse gliomas. These tumors are presently defined based on 
presence/absence of IDH mutation and 1p/19q codeletion. It can be attributed to 
massive expansion of knowledge on molecular alterations in tumors of the central 
nervous system (CNS) [2]. Until now, tumors were defined based on their histol-
ogy. Any molecular information was mainly provided as supplementary informa-
tion within histologically defined categories. Current advances in the molecular 
conceptualization of gliomas recommend some probable reasons for the failure of 
targeted therapies in gliomas. Specially, the histologic-based glioma categorization 
comprises of multiple molecular subtypes with discrete biology, usual history, 
and diagnosis. These observations have resulted in improvement in diagnosis and 
classification by the World Health Organization [7]. These perceptions regarding 
glioma biomarkers and subtypes highlight several clinical challenges. Firstly, the 
field is witnessing the struggle of reconsidering the results of previous studies and 
retrospective data using the new classifications to explain prognostic assessments 
and treatment recommendations for patients. Secondly, the new classification 
requires changes in the design and stratification of future clinical trials. Hence, 
these observations offer the required framework for the growth and evaluation of 
novel targeted therapies for specific glioma subtypes [2, 8].
Drug delivery to tumor can be monitored using nuclear medicine imag-
ing techniques like single-photon emission computed tomography (SPECT), 
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positron-emission-tomography (PET). In single-photon emission computed tomog-
raphy (SPECT), a gamma-emitting tracer allows for three dimensional visualization 
of the drug [9]. The radioisotope is either administered with the drug or directly 
bound to the biologically active molecule such as siRNA, so that their volume of 
 distribution can be determined easily. Accurate anatomic estimates can be obtained 
by combining SPECT with CT or MRI. This approach is less expensive in compari-
son to other nuclear medicine imaging modalities [10]. Conventional SPECT suffer 
from poor limitation. However, recent advances involving pinhole-SPECT has 
improved the resolution to millimeter level [11].
Another promising modality for imaging drug delivery to tumor is positron-
emission-tomography (PET). PET tracers are administered with the drug or are 
bound to the carrier like nanoparticles [12]. The PET scan can be correlated with CT 
scan in order to determine path of diffusion of tracer.
Similar to gadolinium and SPECT contrast agents, PET tracers can be infused 
concurrently with drug or bound to the delivery system, such as nanoparticles [12]. 
When PET is coupled with CT, molecular movement can be correlated with anat-
omy, with measurement of area of diffusion of tracer or tracer-incorporated carrier. 
PET imaging can estimate the borders of a tumor through the use of tracers that 
are derivatives of amino acid such as O-(2-[18F]fluoroethyl)-L-tyrosine (FET) thus 
allowing precise assessment of drug distribution relative to tumor volume than MRI 
[13]. Limitations of PET and SPECT imaging include radiation exposure, the high 
cost, and short-lived nature of PET tracers. Another important limitation similar to 
gadolinium agents in MRI is the tracer has to directly couple to the delivery agent; 
otherwise the measurement of the area of diffusion is indirect. These limitations 
can be overcome by direct radiolabeling of nanoparticles [14].
3.  Nanocarrier-mediated CNS delivery of diagnostic and therapeutic 
agents
Drug delivery across the BBB requires knowledge of both “barrier” and per-
meability properties of the brain endothelial cells. Transport across BBB may 
involve simple diffusion, facilitated diffusion, diffusion through aqueous pores, 
and active transport through protein carriers. In case of simple diffusion solute 
molecules travels along concentration gradient. Facilitated diffusion involves 
binding with specific membrane-traversing protein, coupled with movement along 
the concentration gradient. Charged ions and solutes cross the BBB by diffusion 
through aqueous pores. Active transport of solutes through protein carrier against 
concentration gradient involves expenditure of ATP. The presence of large number 
of mitochondria in the endothelial cells is thought to provide the required energy in 
form of ATP [15]. This mechanism involves an alteration in the affinity of a carrier 
for the solute molecules as it travels across the BBB. While designing nanocarrier 
mediated CNS delivery, transporter systems involved in ferrying essential mol-
ecules such as glucose are of utmost importance. These systems can be employed 
for delivery of potential nanotheranostics across the BBB. There are five types of 
sodium-independent glucose transporters (GLUT) which transport 2-deoxyglu-
cose, 3-O-methylglucose, mannose, galactose and glucose across the BBB. The most 
important being 45–55 kDa glycosylated protein GLUT-1. It is mostly present in 
endothelial cells of arterioles, venules and capillaries, wherein it facilitates move-
ment of D-glucose from the peripheral circulation into the brain. Other worth 
mentioning glucose transporters are GLUT-3 in brain neurons and GLUT-5 in 
microglial cells in the brain. They transport 2-deoxyglucose, 3-O-methylglucose, 
mannose, galactose and glucose across the BBB [16].
Medical Isotopes
4
Another significant transport system that works in an analogous manner is 
P-glycoprotein multiple drug resistant protein (P-gp, MDR1). It has been compre-
hensively investigated as a possible carrier for drug delivery. This efflux transporter 
is usually expressed on luminal surface of endothelial cells, astrocytes and microg-
lial cells. It prevents toxins from gaining entry into the brain parenchyma [17, 18]. 
Anticancer agents like Vinca alkaloids, anthracyclines, and taxanes are substrates 
for MDR1 are transported by Pgp. It limits their accumulation in the brain. Recently, 
it has been found that MDR1 regulation is altered by various disease conditions, 
and, in turn, diseases of the brain influence MDR1 expression [19, 20]. The pres-
ence of large number of receptors at the surface of BBB can be utilized by potential 
nanocarriers for enhanced brain by coupling with receptor-specific molecules or 
analogues. A large number of molecules such as insulin, insulin-like growth factors 
(IGF-1 and IGF-2), leptins, and transferrin can be transported into the brain fol-
lowing receptor-mediated endocytosis [13]. The nanoparticles should be designed 
to bypass efflux transport systems present at the luminal side (such as MDR1). 
Instead, nanoparticles could be substrates of transport mechanisms enhancing the 
passage of specific molecules like GLUT-1, IGF-1, and IGF-2 across the BBB [21].
4. Paradigm shift in glioma diagnosis and treatment strategies
The WHO 2016 Classification of gliomas represents a paradigm shift as; for 
the first time, the definition of many of these neoplasms is partly based on genetic 
characteristics based on molecular markers. This was a major step forward toward a 
more precise diagnosis of gliomas and will in the course of time certainly facilitate 
improved therapeutic management of the patients suffering from these tumors. 
Diffuse gliomas are the most common intrinsic CNS neoplasms, found in adults. On 
the basis of histopathological analysis, these gliomas were conventionally diagnosed 
as diffuse astrocytomas (with glioblastoma as it is most common and malignant 
representative), oligodendrogliomas, or as tumors with a mixed astrocytic and 
oligodendroglial phenotype (oligoastrocytomas) [6]. Within these subgroups, a 
malignancy grade (WHO grade II, III or IV) was assigned based on the presence/
absence of marked mitotic activity, necrosis and florid microvascular prolifera-
tion. The major change can be attributed to use of isocitrate dehydrogenase (IDH 
mutation) as a marker in diffuse glioma classification. The categorization of diffuse 
gliomas on the basis of genotype involves high incidence of point mutations in iso-
citrate dehydrogenase 1 and 2 (IDH1/IDH2) in WHO grade II and III astrocytomas, 
oligodendrogliomas, oligoastrocytomas and secondary glioblastomas. Lower grade 
neoplasms usually develop into secondary glioblastomas [8]. Hence, it became clear 
that tumors with identical histology can lead to different clinical outcome such as 
IDH-wildtype and IDH-mutant diffuse gliomas. Many histologically similar WHO 
grade II and WHO grade III IDH-wild type diffuse gliomas exhibit molecular char-
acteristics like glioblastoma. These facts ultimately led to inclusion of IDH mutation 
as a crucial marker for glioma classification and the introduction of, genetically 
defined entities: diffuse astrocytoma, IDH-mutant; anaplastic astrocytoma, IDH-
mutant; oligodendroglioma, IDH-mutant; anaplastic oligodendroglioma, IDH-
mutant; and glioblastoma, IDH-mutant [7]. The molecular features of IDH-mutant 
glioma outweigh the histological diagnosis. A tumor having histology of an astro-
cytoma, detection of complete 1p/19q codeletion leads to diagnosis of oligodendro-
glioma. Likewise, for diffuse, IDH-mutant gliomas with oligodendroglial phenotype 
with complete absence of 1p/19q codeletion, the collective diagnosis may be astro-
cytoma, IDH-mutant and 1p/19q-non-codeleted [8]. Based on IDH mutation status, 
glioblastomas were reclassified as glioblastoma, IDH-wildtype and glioblastoma, 
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IDH-mutant. This latter category largely overlaps with what previously described 
secondary glioblastoma based on clinical, radiological and/or pathological evidence 
of a lower grade precursor lesion. Patients with a secondary glioblastoma or IDH-
mutant glioblastoma are normally younger and have improved diagnosis than those 
with glioblastoma, IDH-wildtype. Analogous to grade II and grade III oligoastro-
cytic tumors, most glioblastomas with oligodendroglioma as explained in the WHO 
2016 Classification are part of one of the genetic subgroups of diffuse glioma [7, 8]. 
One of the treatment strategies which are catching the attention of oncologist is 
nanotechnology. Nanoparticles (NP) are entities possessing diameter of 10–200 nm 
that hold great possibilities for design and biological applications. There has been 
an upsurge in development of nanodevices for diagnosis and treatment of brain 
tumors. Nanoparticles are carriers that can be designed to ferry one or more types 
of molecules to brain including MRI contrast agents, fluorescent and visible dyes, 
chemotherapeutic agents and photosensitizers. The targeted delivery of nanopar-
ticles to brain tumors can be augmented by altering their particle size and surface 
characteristics [22, 23].
5. Multimodal tumor imaging and therapy
There has been moderate impact of targeted therapies in glioma. The therapies 
that have demonstrated a significant survival benefit for gliomas in Phase III clinical 
trials, including radiation, chemotherapy (temozolomide and PCV [procarbazine, 
lomustine, vincristine]), and tumor-treating fields, are based on nonspecific 
targeting of proliferating cells. An emerging field in glioblastoma nuclear medicine 
is use of radionanoparticles. These radioactive nanocarriers can be used passively 
as a simple tumor brachytherapy or can be actively used with a specific targeting to 
vectorize a large amount of radioactivity. The targeting is usually directed against 
a glioblastoma-specific antigen or receptor. Antigen targets, like epidermal growth 
factor receptor (EGFR), tenascin, or DNA histone H1 complex. Radiolabeled 
antibodies and peptides hold promise for molecular radiotherapy but are often 
limited by a low payload resulting in inadequate delivery of radioactivity to tumor 
tissue and, therefore, inadequate therapeutic effect and adverse effects due irradia-
tion of normal tissues [24]. Song et al. developed a synthetic method of radiola-
beling indium-111 (111In) to epidermal growth factor (EGF)-gold nanoparticles 
(111In-EGF-Au NP) with a high payload [25]. By using radiolabeled nanoparticles, 
comparatively higher payloads are obtained due to large surface area to volume 
ratio. This results in multivalent effect of nanoparticles, thus accommodating a 
large number of targeting ligands, such as antibodies, peptides or aptamers on a 
single nanoparticle. This facilitates maximal binding to the molecular target in vivo, 
thus enhancing delivery of radioactivity to target tissue with improved imag-
ing and therapeutic efficacy. PEGylation of nanoparticles and alteration of their 
surface properties improves their stability and mean residence time in vivo [26]. 
It also permits loading a combination of imaging, radiotherapeutic and/or chemo-
therapeutic moieties for multimodal tumor imaging and therapy [27]. Antibodies, 
radiolabeled antibodies, antibody fragments or peptides because of their small size 
easily penetrate surrounding normal tissues. Loading onto nanoparticles limits 
their penetration through normal vasculature and capillaries, thus minimizing their 
side-effects [28].
Different nanocarriers such as metallofullerenes, liposomes, or lipid nanocap-
sules have been used to deliver radionanoparticle passively. A typical metallofuller-
ene (177Lu-DOTA-f-Gd3N@C80) radionanoparticles when administered by 
convection-enhanced delivery (CED) in brain tumor model showed an improved 
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survival time of more than 2.5 times that of the control group [29]. Similarly 
liposomes loaded with beta-negative emitters such rhenium-186 and demonstrated 
promising results when administered by CED in an orthotopic glioblastoma rat 
model [30]. Lipid nanocapsules loaded with rhenium-188 in a rat orthotopic model 
showed a significant survival benefit after intratumoral stereotactic injection at day 
6 and CED injection at day 12 [31].
A recent approach using radionanoparticles consists of an active targeting 
approach where the nanoparticles are functionalized and directed against a tumor 
target. The aim of this active targeting is to optimize the spatial localization of the 
radioactivity close to the tumor cells. As an example, lipid nanocapsules can be 
loaded with rhenium-188 and coupled to a monoclonal antibody directed against 
the CXCR4 antigen. These CXCR4-recognizing immune-nanoparticles irradiate the 
tumor cells and have been shown to increase efficacy in an orthotopic mouse model. 
Recurrence for the passive protocol was observed at 65 versus 100 days for the 
active targeting approach, and this appears to be the most effective therapy with the 
longest measured time to progression [32].
6. Neural stem cells functionalized with radiolabeled nanoparticles
Neural stem cells (NSCs) are increasingly being used as carriers for targeted 
delivery of therapeutics to glioblastoma. This requires multimodal dynamic in vivo 
imaging of NSC in the brain. Such type of technology is in development phase. 
Cheng et al. reported an innovative strategy for neural stem cell tracking in brain 
using silica nanoparticles via SPECT [33]. 111In radioisotopes were conjugated to 
porous silica nanoparticles having large surface area. A series of nanomaterial 
characterization assays were performed to evaluate the modified mesoporous silica 
nanoparticles. Loading efficiency and viability of NSCs with 111In-MSN complex 
was validated. Radiolabeled NSCs were administered to glioma-bearing mice via 
intracranial or systemic injection. SPECT and bioluminescence imaging were per-
formed periodically after NSC injection. Histology and immunocytochemistry were 
performed to endorse the findings. 111In-MSN complexes showed minimal toxic-
ity to NSCs and adequate in vitro and in vivo stability. Phantom studies establish 
possibility of mesoporous silica nanoparticles for NSC imaging. It was found that 
decayed 111In-MSN complexes exhibited significant fluorescent profiles in preloaded 
NSCs, thus validating ex vivo data. In vivo, SPECT images reveal actively migrating 
NSCs toward glioma xenografts in real time after both intracranial and systemic 
injection. This is in consonance with findings of histology, confocal microscopy and 
bioluminescence live imaging [33].
7. Conclusion
An urgent requirement for rapid detection and diagnosis of diseases has led to 
development of contrast agents and imaging techniques. The present challenge is 
for fast and complete imaging of tissues and lesion categorization that could be 
obtained by development of nontoxic contrast agents with longer blood circula-
tion time. Nanotechnology provides apt solution to this problem. Nanoparticle 
based contrast agents have been employed in most biomedical imaging techniques 
like MRI, fluorescence imaging, CT, ultrasound, PET and SPECT. However, these 
imaging techniques have certain limitations. These can be overcome by use of 
multifunctional nanoplatforms to enhance safety, efficacy and theranostic attri-
butes. The WHO 2016 Classification is a major step forward toward a more precise 
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diagnosis of gliomas and will in the course of time certainly facilitate improved 
therapeutic management of the patients suffering from these tumors. The paradigm 
shift is IDH mutation as a marker in diffuse glioma classification and reclassifica-
tion of glioblastoma. Novel drug delivery approaches have substantially influenced 
the glioblastoma treatment. There is urgent requirement of smart delivery systems 
for future therapies targeted to specific cells, dependent on intracellular delivery 
of agents impermeable to BBB. Polymer implants, convection enhanced delivery 
and degradable nanoparticles are some of the platform technologies for design of 
novel methods for treatment of glioblastoma. One strategy to optimize the effi-
cacy of molecularly targeted radionuclide agents is to develop nanoparticle-based 
targeted delivery systems. An abundance of receptors at the surface of the BBB can 
be utilized by nanoparticles for enhanced brain uptake by coupling with receptor-
specific molecules or analogues. The nanoparticles should be designed to bypass 
efflux transport systems present at the luminal side (such as MDR1). Instead, 
nanoparticles could be substrates of transport mechanisms enhancing the passage 
of specific molecules like GLUT-1, IGF-1, and IGF-2 across the BBB. Radiolabelled 
nanoparticles seem to be novel promising arsenal for potential neurotheranostics.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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